International Association for the Study of Lung Cancer’s Post

#ICYMI: 💊 Updated follow-up results from the phase 3 TOPAZ-1 study revealed that #durvalumab with chemotherapy can improve OS in patients with advanced #cholangiocarcinoma. Learn more about the 3-year follow-up results: #BileDuctCancer

💊 Updated follow-up results from the phase 3 TOPAZ-1 study revealed that #durvalumab with chemotherapy can improve OS in patients with advanced #cholangiocarcinoma. Learn more about the 3-year follow-up results: #BileDuctCancer

In this systematic review and network meta-analysis of 27 randomized clinical trials (including a total of 13 413 individuals), the pCR rates achieved with total neoadjuvant therapy regimens outperformed standard long-course chemoradiotherapy, with long-course chemoradiotherapy plus consolidation chemotherapy showing the greatest effect estimate.

In this episode of #OncLiveOnAir, Dr Westin discusses the FDA approval of durvalumab plus chemotherapy for patients with dMMR advanced or recurrent #EndometrialCancer. #gyncsm https://lnkd.in/g3fKWpTx

🔬 Exciting Updates in Clinical Trials! 🔬 🔹 Viridian Strive clinical trial is currently seeking Thyroid Eye Disease (TED) adult subjects! Eligible individuals can refer via the chat function on CockerhamMD.com for an intravenous dose of either 3 or 10 mg. Notably, there is no placebo arm for this trial. 🔹 Horizon/Amgen has successfully recruited their first subject for a clinical trial focusing on the transcutaneous delivery of a modified Tepezza molecule. The randomized process for this study is set to commence on July 9th. 🔹 In another recent development, the Genentech/Roche clinical trial is now live, with a primary focus on evaluating the efficacy of an IL6 monoclonal antibody. Stay tuned for more updates on these groundbreaking clinical trials! 🌟 #ClinicalTrials #Healthcare #MedicalResearch

Time to go back to the future? Below is a link to a nice piece of work from EBRI regarding site-of-care for biologics and biosimilars. Many understand that hospital outpatient departments ("HOPDs," including physician offices that are now billed by health systems as outpatient facilities) generally cost health plans 2, 3, or 4 times the cost of infusions in independent physician offices ("POs"). As such, many plan have moved non-oncology infusions to POs. However, moving oncology infusions to POs is still viewed by most to be one of the "bleeding/leading edges" of cost management. Yet, this paper reports that in 2004, 94% of chemotherapy infusions took place in POs. And, then by 2014, this number dropped to 57%. https://lnkd.in/eNp4_4a2

Explore the Phase 3 ARASAFE trial at #EAU24 📆 The trial compares 2 different dosing schedules of anti-mitotic chemotherapy in combination with an ARPI +ADT in patients with #mHSPC. #ProstateCancer 

Excellent news from ImmunoGen, which was recently acquired by AbbVie. ELAHERE is the first antibody-drug conjugate (ADC) to be approved for the treatment of ovarian cancer. Data from a Phase 3 trial showed that ELAHERE treatment reduces the risk of cancer progression by 35% and improves overall survival by 33%. Ovarian cancer is the leading cause of gynecologic cancer death in the U.S., and most patients present with late-stage disease. The current standard of care is treatment with conventional platinum-based chemotherapy but the majority of patients eventually develop resistance to these drugs. ELAHERE is a targeted therapy for patients with folate receptor-alpha (FRα) positive, platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Over 80% of ovarian tumors express FRα on their cell surface, and increased expression is associated with more aggressive tumors. ELAHERE targets these receptors via an FRα-binding antibody linked to DM4, a drug designed to kill actively dividing tumor cells. These are exciting, game-changing times for cancer treatment! 🦀💊⚕️

Mirvetuximab soravtansine-gynx approved: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer

RPT: Battles of the Alphas Breakthrough Therapy Designation is based on the results from phase 1 and the ongoing phase 2 clinical trials that assessed the safety and efficacy of AlphaMedixTM. In the phase 1 study, treatment was well-tolerated, with a response rate (ORR according to RECIST 1.1) of 62.5% for the GEP-NET patients who had never received PRRT with LutatheraTM, which is based on the beta-particle emitter Lutetium-177. In the phase 2 trial, the target response rate has already been achieved ahead of top-line data, expected in mid-2024.